Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma

BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease urgently requiring new treatments. Over-expression of the protein transporter exportin-1 (XPO1) leads to mislocalization of tumor suppressor proteins (TSPs) and their inactivation. Earlier, we showed that blocking...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Azmi, Asfar S., Khan, Husain Yar, Aboukameel, Amro, Muqbil, Irfana, Neggers, Jasper E., Daelemans, Dirk, Mahipal, Amit, Dyson, Gregory, Kamgar, Mandana, Al-Hallak, Mohammad Najeeb, Tesfaye, Anteneh A., Kim, Steve, Shidham, Vinod, Mohammad, Ramzi M., Philip, Philip A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7073299/
https://ncbi.nlm.nih.gov/pubmed/31831564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1728
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados